Review



galectin 3 gal 3 immunoreactivity  (Galectin Therapeutics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Galectin Therapeutics galectin 3 gal 3 immunoreactivity
    Analysis of galectin expression in the spleen. A – D : Galectin-1 (Gal-1) immunoreactivity. E–H <t>:</t> <t>Galectin-3</t> <t>(Gal-3)</t> immunoreactivity. I–L : Galectin-9 (Gal-9) immunoreactivity. Immunolabeling is observed in both white pulp (wp) and red pulp (rp), with differences in distribution and intensity among groups: SHAM (control animals), MCP (animals treated with MCP), CIS (animals treated with cisplatin), and MCP + CIS (animals treated with MCP and cisplatin). Counterstain: Carazzi’s hematoxylin. Scale bars: 100 μm. M–O : Densitometric analysis of Gal-1, Gal-3, and Gal-9 immunoreactivity in splenic tissue. Data represent the mean ± SEM of arbitrary units (a.u.) of protein expression ( n = 5 animals/group). * p < 0.05; ** p < 0.01, *** p < 0.001; **** p < 0.0001 (M, O, Q-S: ANOVA followed by post-hoc Tukey test; N: Kruskal-Wallis followed by post-hoc Dunn’s test)
    Galectin 3 Gal 3 Immunoreactivity, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+3+gal+3+immunoreactivity/lgals3/pmc13171650-126-2-2
    Average 86 stars, based on 1 article reviews
    galectin 3 gal 3 immunoreactivity - by Bioz Stars, 2026-09
    86/100 stars

    Images

    1) Product Images from "Modified citrus pectin modulates splenic immune responses and galectin expression following cisplatin treatment in Wistar rats"

    Article Title: Modified citrus pectin modulates splenic immune responses and galectin expression following cisplatin treatment in Wistar rats

    Journal: Journal of Molecular Histology

    doi: 10.1007/s10735-026-10828-w

    Analysis of galectin expression in the spleen. A – D : Galectin-1 (Gal-1) immunoreactivity. E–H : Galectin-3 (Gal-3) immunoreactivity. I–L : Galectin-9 (Gal-9) immunoreactivity. Immunolabeling is observed in both white pulp (wp) and red pulp (rp), with differences in distribution and intensity among groups: SHAM (control animals), MCP (animals treated with MCP), CIS (animals treated with cisplatin), and MCP + CIS (animals treated with MCP and cisplatin). Counterstain: Carazzi’s hematoxylin. Scale bars: 100 μm. M–O : Densitometric analysis of Gal-1, Gal-3, and Gal-9 immunoreactivity in splenic tissue. Data represent the mean ± SEM of arbitrary units (a.u.) of protein expression ( n = 5 animals/group). * p < 0.05; ** p < 0.01, *** p < 0.001; **** p < 0.0001 (M, O, Q-S: ANOVA followed by post-hoc Tukey test; N: Kruskal-Wallis followed by post-hoc Dunn’s test)
    Figure Legend Snippet: Analysis of galectin expression in the spleen. A – D : Galectin-1 (Gal-1) immunoreactivity. E–H : Galectin-3 (Gal-3) immunoreactivity. I–L : Galectin-9 (Gal-9) immunoreactivity. Immunolabeling is observed in both white pulp (wp) and red pulp (rp), with differences in distribution and intensity among groups: SHAM (control animals), MCP (animals treated with MCP), CIS (animals treated with cisplatin), and MCP + CIS (animals treated with MCP and cisplatin). Counterstain: Carazzi’s hematoxylin. Scale bars: 100 μm. M–O : Densitometric analysis of Gal-1, Gal-3, and Gal-9 immunoreactivity in splenic tissue. Data represent the mean ± SEM of arbitrary units (a.u.) of protein expression ( n = 5 animals/group). * p < 0.05; ** p < 0.01, *** p < 0.001; **** p < 0.0001 (M, O, Q-S: ANOVA followed by post-hoc Tukey test; N: Kruskal-Wallis followed by post-hoc Dunn’s test)

    Techniques Used: Expressing, Immunolabeling, Control

    Correlation analysis of galectin expression and splenic immune cell populations between CIS and MCP + CIS groups. A , B : Correlation analyses show no significant correlations between galectin expression (Gal-1, Gal-3, and Gal-9) and CD68⁺ macrophages or CD3⁺ T cells in the CIS group. C : Correlation analysis indicating positive associations between Gal-1, Gal-3, and Gal-9 expression and the CD68 + macrophage population in the MCP + CIS group. D : Correlation analysis showing a positive association between Gal-3 expression and CD3⁺ T cells in the MCP + CIS group. Correlation analyses were performed using Pearson or Spearman tests, depending on the data distribution ( n = 5 animals/group). * p < 0.05; *** p < 0.001; **** p < 0.0001
    Figure Legend Snippet: Correlation analysis of galectin expression and splenic immune cell populations between CIS and MCP + CIS groups. A , B : Correlation analyses show no significant correlations between galectin expression (Gal-1, Gal-3, and Gal-9) and CD68⁺ macrophages or CD3⁺ T cells in the CIS group. C : Correlation analysis indicating positive associations between Gal-1, Gal-3, and Gal-9 expression and the CD68 + macrophage population in the MCP + CIS group. D : Correlation analysis showing a positive association between Gal-3 expression and CD3⁺ T cells in the MCP + CIS group. Correlation analyses were performed using Pearson or Spearman tests, depending on the data distribution ( n = 5 animals/group). * p < 0.05; *** p < 0.001; **** p < 0.0001

    Techniques Used: Expressing



    Similar Products

    galectin 3 gal 3 immunoreactivity  (Galectin Therapeutics)
    86
    Galectin Therapeutics galectin 3 gal 3 immunoreactivity
    Analysis of galectin expression in the spleen. A – D : Galectin-1 (Gal-1) immunoreactivity. E–H <t>:</t> <t>Galectin-3</t> <t>(Gal-3)</t> immunoreactivity. I–L : Galectin-9 (Gal-9) immunoreactivity. Immunolabeling is observed in both white pulp (wp) and red pulp (rp), with differences in distribution and intensity among groups: SHAM (control animals), MCP (animals treated with MCP), CIS (animals treated with cisplatin), and MCP + CIS (animals treated with MCP and cisplatin). Counterstain: Carazzi’s hematoxylin. Scale bars: 100 μm. M–O : Densitometric analysis of Gal-1, Gal-3, and Gal-9 immunoreactivity in splenic tissue. Data represent the mean ± SEM of arbitrary units (a.u.) of protein expression ( n = 5 animals/group). * p < 0.05; ** p < 0.01, *** p < 0.001; **** p < 0.0001 (M, O, Q-S: ANOVA followed by post-hoc Tukey test; N: Kruskal-Wallis followed by post-hoc Dunn’s test)
    Galectin 3 Gal 3 Immunoreactivity, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+3+gal+3+immunoreactivity/lgals3/pmc13171650-126-2-2
    Average 86 stars, based on 1 article reviews
    galectin 3 gal 3 immunoreactivity - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Analysis of galectin expression in the spleen. A – D : Galectin-1 (Gal-1) immunoreactivity. E–H : Galectin-3 (Gal-3) immunoreactivity. I–L : Galectin-9 (Gal-9) immunoreactivity. Immunolabeling is observed in both white pulp (wp) and red pulp (rp), with differences in distribution and intensity among groups: SHAM (control animals), MCP (animals treated with MCP), CIS (animals treated with cisplatin), and MCP + CIS (animals treated with MCP and cisplatin). Counterstain: Carazzi’s hematoxylin. Scale bars: 100 μm. M–O : Densitometric analysis of Gal-1, Gal-3, and Gal-9 immunoreactivity in splenic tissue. Data represent the mean ± SEM of arbitrary units (a.u.) of protein expression ( n = 5 animals/group). * p < 0.05; ** p < 0.01, *** p < 0.001; **** p < 0.0001 (M, O, Q-S: ANOVA followed by post-hoc Tukey test; N: Kruskal-Wallis followed by post-hoc Dunn’s test)

    Journal: Journal of Molecular Histology

    Article Title: Modified citrus pectin modulates splenic immune responses and galectin expression following cisplatin treatment in Wistar rats

    doi: 10.1007/s10735-026-10828-w

    Figure Lengend Snippet: Analysis of galectin expression in the spleen. A – D : Galectin-1 (Gal-1) immunoreactivity. E–H : Galectin-3 (Gal-3) immunoreactivity. I–L : Galectin-9 (Gal-9) immunoreactivity. Immunolabeling is observed in both white pulp (wp) and red pulp (rp), with differences in distribution and intensity among groups: SHAM (control animals), MCP (animals treated with MCP), CIS (animals treated with cisplatin), and MCP + CIS (animals treated with MCP and cisplatin). Counterstain: Carazzi’s hematoxylin. Scale bars: 100 μm. M–O : Densitometric analysis of Gal-1, Gal-3, and Gal-9 immunoreactivity in splenic tissue. Data represent the mean ± SEM of arbitrary units (a.u.) of protein expression ( n = 5 animals/group). * p < 0.05; ** p < 0.01, *** p < 0.001; **** p < 0.0001 (M, O, Q-S: ANOVA followed by post-hoc Tukey test; N: Kruskal-Wallis followed by post-hoc Dunn’s test)

    Article Snippet: E–H : Galectin-3 (Gal-3) immunoreactivity.

    Techniques: Expressing, Immunolabeling, Control

    Correlation analysis of galectin expression and splenic immune cell populations between CIS and MCP + CIS groups. A , B : Correlation analyses show no significant correlations between galectin expression (Gal-1, Gal-3, and Gal-9) and CD68⁺ macrophages or CD3⁺ T cells in the CIS group. C : Correlation analysis indicating positive associations between Gal-1, Gal-3, and Gal-9 expression and the CD68 + macrophage population in the MCP + CIS group. D : Correlation analysis showing a positive association between Gal-3 expression and CD3⁺ T cells in the MCP + CIS group. Correlation analyses were performed using Pearson or Spearman tests, depending on the data distribution ( n = 5 animals/group). * p < 0.05; *** p < 0.001; **** p < 0.0001

    Journal: Journal of Molecular Histology

    Article Title: Modified citrus pectin modulates splenic immune responses and galectin expression following cisplatin treatment in Wistar rats

    doi: 10.1007/s10735-026-10828-w

    Figure Lengend Snippet: Correlation analysis of galectin expression and splenic immune cell populations between CIS and MCP + CIS groups. A , B : Correlation analyses show no significant correlations between galectin expression (Gal-1, Gal-3, and Gal-9) and CD68⁺ macrophages or CD3⁺ T cells in the CIS group. C : Correlation analysis indicating positive associations between Gal-1, Gal-3, and Gal-9 expression and the CD68 + macrophage population in the MCP + CIS group. D : Correlation analysis showing a positive association between Gal-3 expression and CD3⁺ T cells in the MCP + CIS group. Correlation analyses were performed using Pearson or Spearman tests, depending on the data distribution ( n = 5 animals/group). * p < 0.05; *** p < 0.001; **** p < 0.0001

    Article Snippet: E–H : Galectin-3 (Gal-3) immunoreactivity.

    Techniques: Expressing